Safety first, efficacy second in disease modifying therapies
The last 15 years have seen the increasing use of disease-modifying therapies (DMTs) for relapsing multiple sclerosis (MS) and a corresponding increase in our understanding of their mechanisms of action, limitations, and side-effects. Observational studies involving large cohorts of patients over many years are important in highlighting aspects of both safety and efficacy. In this edition of the journal, two papers deal with concerns of safety in relation to the use of subcutaneous interferon beta-1 a. 1, 2 
Cancer and MS
Although an increased risk for certain forms of cancer had been suggested, 3 this has not been confirmed in studies using multiple MS centres' databases, health service record linkage data and national MS registers. These newer studies from the UK, 4 Sweden, 5 France 6 and Denmark, 7 involving large cohorts followed for significant periods have shown no evidence linking MS with an increased risk of cancer. In contrast, the surprising finding is that, by meta-analysis, that there is a small but significant reduction of total cancer risk in patients with multiple sclerosis (odds ratio [OR] 0.92; 95% confidence interval [CI] 0.87-0.97, p ¼ 0.004). 8 It does not seem that this reduced risk relates to the increased mortality due to MS but may reflect changes in diet and smoking cessation, or immunological effects of having MS. 8 Although having MS may have some protective effect against cancer, there is still a question about the long-term risks of DMTs and cancer. The French study indicated an increased risk of breast cancer among MS patients treated with immunosuppressive therapy. 6 However a small increased risk (RR 1.54, 95% CI 1.2-2.0) for breast cancer was also noted in the Danish study which followed patients to 1997 and was unlikely to have included patients treated with immunosuppressive therapies or DMTs for any significant time. 7 It could be argued that the effects of DMTs and risk of cancer may not appear until after 10 or more years of treatment and thus the data from these studies many of which stopped in the 1990s may not reflect the potential risk from DMTs. Thus, the study of data collected on subcutaneous interferon beta-1 a is welcome since it reflects reports from 1998 to 2009. 1 Although acknowledging potential biases in the dataset, overall the results are consistent with the impression that cancer rates are lower in MS than the general population and there is no evidence that malignancy is more common with treatment with subcutaneous interferon beta-1 a.
Pregnancy and MS immunomodulation
The safety of first-line DMTs in everyday practice is emphasized by the reports of pregnancy outcomes in women with MS who have been inadvertently exposed to DMTs post-conception. The evidence, from the study in this edition of the journal 2 and other small observational studies, is that early in utero exposure to interferon betas does not appear to increase spontaneous abortions and is not detrimental to the infant. [9] [10] [11] [12] Although in one series of patients treated with interferon betas pregnancy loss was higher than expected, 13 a recent Italian study reported no increased risk of spontaneous abortion in their 88 pregnancies inadvertently treated with DMTs for a mean of 4 weeks of gestation. These authors suggested that, in order to avoid the risk of relapse caused by stopping DMTs before conception, one might consider continuing DMTs until a early pregnancy test is positive. 10 Some have gone so far as to suggest that glatiramer acetate may be safely continued throughout pregnancy and the post-partum period in patients with high relapse rate in the pre-pregnancy year. 14 These authors have suggested that the risk/benefits should be discussed with patients and that those pregnancies in which therapy is continued should be entered in a global anonymized database to collect meaningful data. However, continuing therapy during pregnancy exposes patients to unquantified risks without clear additional benefit since pregnancy has an immunomodulating effect on MS considered greater than any of the conventional DMTs. 15 Therefore, in relation to both safety and efficacy, despite the apparently benign outcome in pregnancies with exposure to DMTs in the first few weeks of gestation, the standard of discontinuing DMTs prior to conception should be continued.
The risk period for increased disease activity is the post-partum period and women, after appropriate counselling, who decide not to breastfeed should be started back on their DMT immediately after delivery. Although some have suggested that exclusive breastfeeding is associated with disease suppression in the post-partum period, 16 others do not agree. 17, 18 An confounding factor in such studies is that it is women with less active disease who are much more likely to breastfeed, exclusively or not. A truly randomized prospective study of breast feeding and post-partum relapse rates is an improbable future event. Until convincing evidence emerges, restarting DMTs as soon as possible postpartum should be considered in women with more active MS.
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